Renalytix (LON:RENX) Insider Christopher Mills Sells 1,166,667 Shares of Stock

Renalytix Plc (LON:RENX) insider Christopher Mills sold 1,166,667 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of GBX 6, for a total transaction of £70,000.02.

Renalytix Trading Up 0.7%

Shares of RENX traded up GBX 0.04 during mid-day trading on Thursday, reaching GBX 6.14. The stock had a trading volume of 1,187,215 shares, compared to its average volume of 1,100,340. Renalytix Plc has a 52-week low of GBX 1.60 and a 52-week high of GBX 10. The firm has a market cap of £26.85 million, a price-to-earnings ratio of -1.54 and a beta of 1.81. The business’s fifty day moving average is GBX 4.47 and its 200 day moving average is GBX 2.93. The company has a debt-to-equity ratio of -483.33, a current ratio of 1.57 and a quick ratio of 2.42.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).